The Stubborn Stalemate in Cannabis Rescheduling
As the debate heats up over moving cannabis from Schedule I to Schedule III, the resistance from former DEA leaders and White House drug czars is a stark reminder of how far removed some policy stances are from public opinion and scientific evidence. These officials argue that rescheduling would “supersize” the cannabis industry, yet this perspective blatantly ignores the will of the people and the growing body of research affirming cannabis’s medical benefits. This ongoing battle isn’t just a policy dispute; it’s a glaring example of how entrenched, outdated views continue to hinder progress and overlook the proven therapeutic potential of cannabis.
State AGs & Former DEA heads want cannabis scheduling hearing (Newsletter: June 21, 2024)